Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis

• Published in: Cancer pathogenesis and therapy Vol. 1; no. 3; pp. 195 - 204
• Main Authors: Shree, Bakhya, Das, Koyel, Sharma, Vivek
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2023; Elsevier
• Subjects: Androgen deprivation therapy; Androgen-independent prostate cancer; Benign prostatic hyperplasia; Castration-resistant prostate cancer; LncRNA; Prostate cancer; Prostate-specific antigen; Review; TGF-β; Castration-resistant prostate cancer; Androgen deprivation therapy; Prostate-specific antigen; LncRNA; TGF-β; Benign prostatic hyperplasia; Androgen-independent prostate cancer; Prostate cancer
• ISSN: 2949-7132; 2097-2563; 2949-7132
• DOI: 10.1016/j.cpt.2022.12.003

Prostate cancer (PCa) is the most common malignancy in men. Despite aggressive therapy involving surgery and hormonal treatments, the recurrence and emergence of metastatic castration-resistant prostate cancer (CRPCa) remain a major challenge. Dysregulation of the transforming growth factor-β (TGF-β) signaling pathway is crucial to PCa development and progression. This also contributes to androgen receptor activation and the emergence of CRPC. In addition, TGF-β signaling regulates long non-coding RNA (lncRNA) expression in multiple cancers, including PCa. Here, we discuss the complex regulatory network of lncRNAs and TGF-β signaling in PCa and their potential applications in diagnosing, prognosis, and treating PCa. Further investigations on the role of lncRNAs in the TGF-β pathway will help to better understand PCa pathogenesis. [Display omitted] •Long non-coding RNAs (lncRNAs) regulate prostate cancer (PCa) pathogenesis.•LncRNAs act as effectors and regulators of the transforming growth factor-β (TGF-β) pathway in PCa.•The TGF-β pathway is closely related to androgen receptor (AR) signaling.•TGF-β-regulated lncRNAs are potential biomarkers and therapeutic targets for PCa.